Key Questions: THE BEST FIRST LINE (II)
•
The monoclonal antibodies shown to improve of clinical outcome when
combined with polichemotherapy in the first line setting (EVIDENCE LEVEL IB)
PEAK
Rivera F. y cols. J Clin Oncol.2013
•
Primary END POINT: PFS in KRASWT (EX 2)
•
Secundary prespecified: OS in RASwt (EX K-NRAS2-4)
Pmab-QT
Bv-QT
PFS KRASwt 10,9 m
10,1 m
PFS RASwt 13.0 m
10,1 m
OS KRASwt 34,2 m
24,3 m
OS RASwt
41,3 m
28,9 m
P=.35
P=.03
P=.009
P=.058
36
